Other psychoactive substance abuse
ICD-10 F19.1 is a billable code used to indicate a diagnosis of other psychoactive substance abuse.
F19.1 refers to the abuse of psychoactive substances that do not fall under the more commonly classified categories such as alcohol, opioids, or stimulants. This includes substances like hallucinogens, inhalants, and other drugs that can lead to significant impairment or distress. Patients may present with a range of symptoms including cravings, withdrawal symptoms, and behavioral changes. The diagnosis of substance abuse requires a pattern of use that leads to clinically significant impairment or distress, as evidenced by recurrent substance-related legal problems, social or interpersonal issues, or neglect of major responsibilities. Treatment often involves a combination of behavioral therapies, counseling, and support groups, with a focus on addressing both the psychological and physical aspects of addiction. Withdrawal symptoms can vary widely depending on the substance involved, and may require medical intervention to manage safely. Accurate coding is essential for appropriate treatment planning and reimbursement.
Detailed substance use history, including types and amounts of substances used, duration of use, and previous treatment attempts.
Patients presenting with withdrawal symptoms, those seeking detoxification, or individuals in need of rehabilitation services.
Documentation must clearly differentiate between abuse and dependence, and include any co-occurring mental health conditions.
Comprehensive mental health evaluation, including assessment of mood, behavior, and any psychiatric comorbidities.
Patients with dual diagnoses, such as depression or anxiety alongside substance abuse.
Psychiatric evaluations should include a thorough review of the patient's psychosocial history and any previous treatment for substance use.
Used when assessing a patient for substance abuse treatment.
Document the assessment findings and treatment recommendations.
Addiction specialists should ensure comprehensive evaluations are performed.
F19.1 includes a variety of psychoactive substances not classified under specific categories, such as hallucinogens, inhalants, and other drugs that can lead to abuse.
Substance abuse is characterized by harmful use leading to significant impairment, while dependence involves a physical or psychological reliance on the substance, often with withdrawal symptoms.
